Companies Forge Ahead
PRC Awaiting U.S./EU/WHO Biosimilars Guidance
By Cornelia Zou
Wednesday, October 23, 2013
HONG KONG – Defying all expectations of an early announcement, biosimilar developers in China are unlikely to see any kind of regulatory framework in the near future.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.